Redefining what's possible in genetic analysis

Introducing our work

Here at Depixus we are developing a platform for analysing the genomics of biological systems at new levels of resolution.

Our MAGNATM technology goes beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.

We analyse single native molecules of DNA, RNA and protein to bring new insights across important emerging areas of biology.

 

Senior Team

Board Members

Investors

Early-stage investors

Depixus has strong backing from experienced early-stage investors, several of whom are veterans of the sequencing industry.

Other

We are also supported financially via a variety of grants and awards.

Venture Capital

Depixus is also backed by Arix Bioscience Limited, a global venture capital company focussed on investing in and building breakthrough biotechnology companies around cutting-edge advances in the life sciences.